Slovenian Chemical Society awards Lek scientists for outstanding achievements in the field of chemistry
- At this year's Slovenian Chemistry Days, Slovenian Chemical Society awards were presented for the first time, with Lek scientists from Sandoz Development Center Slovenia being among this year's winners.
- They received the award for excellence in chemistry in the category of economic activities.
- Their research has contributed to making high blood pressure medicines available to patients around the world.
The Slovenian Chemistry Days 2024 event took place from 18 to 20 September at the congress center of Grand Hotel Bernardin in Portorož. This year, for the first time at the event, Slovenian Chemical Society awards were presented, and Lek's team of experts from Sandoz Development Center Slovenia received the award for outstanding achievements in the field of chemistry in the category of economic activity.
Lek's team of scientist, consisting of dr. Rok Grahek, dr. Miha Drev, dr. Borut Zupančič, Matej Ošlaj, Andrej Bastarda, dr. Andrej Kocijan and prof. dr. Zdenko Časar, received the award for their solution regarding the safety of medicines containing the active ingredient hydrochlorothiazide (HCT), which is used for the treatment of high blood pressure.
"We are proud that the Slovenian Chemical Society at these first-ever trade awards has recognized the excellence and breakthrough research work of our experts, whose work has made medicines for the treatment of high blood pressure accessible to patients around the world," said Matjaž Tršek, Head of Sandoz Development Center Slovenia and member of the Sandoz Slovenia Leadership team.
The award, which was presented during the Slovenian Chemistry Days 2024 event, was accepted by Lek scientists prof. dr. Zdenko Časar, Head of Early Pharmaceutical Product Development at Sandoz Development Center Slovenia, and dr. Rok Grahek, Head of Analytical Development at Sandoz Development Center Slovenia. Prof. dr. Zdenko Časar also prepared a plenary lecture entitled Boron in the Synthesis of Active Substances.
At Lek, we are proud to build on our tradition, innovation and breakthroughs in order to introduce a number of new products to global markets. We contribute to improving the quality of life of patients around the world with our dedication, professionalism and high level of responsibility. The Slovenian Chemical Society award for outstanding achievement received by Lek's experts at the Slovenian Chemistry Days 2024 event is proof that Lek's efforts are being recognized by the wider professional public.
About Lek
Lek, a Sandoz company, is the first and oldest pharmaceutical company in Slovenia, developing, manufacturing and marketing effective, safe and high-quality generics and biosimilars for patients around the world. Our work is guided by strong ethical standards, innovative thinking and the breakthrough achievements of our world-class professionals. With more than 3,700 associates, we have been actively shaping the Slovenian, European and global research and development landscape for decades. We are building a culture of open dialog, and we proudly and responsibly hold the title of most reputable employer in Slovenia.
About Sandoz
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 800 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the first biosimilar in 2006. In 2023, Sandoz recorded sales of USD 9.6 billion.
Disclaimer
This Media Release contains forward-looking statements which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
Photo for print
Photo for print
Previous press releases
Contact us
Mojca Pavlin
info.lek@sandoz.com